Share

CureVac partners with Bayer to accelerate vaccine production

Franz-Werner Haas, CureVac CEO says it has initiated a phase 2b-3 trial and expects to enroll 35,000 people in Europe and Latin America. He joins 'Closing Bell' to discuss.
04:24
Tue, Jan 12 20214:30 PM EST